Categories: News

aTyr Pharma to Present at BIO CEO & Investor Digital Conference

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Digital Conference, which is being held February 16 – 18, 2021.

The presentation will be available on-demand for registered attendees of the conference to view. For more information please visit the Company Presentations section on the conference website. A replay of the presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com and will be available or 30 days following the event.

Company management will also participate in virtual one-on-one meetings during the conference. Meetings can be scheduled through the conference partnering system or by contacting investorrelations@atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

Staff

Recent Posts

Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy

Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF)…

29 minutes ago

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

2 hours ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

2 hours ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

2 hours ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

2 hours ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

2 hours ago